Table 2.
Imatinib efficacy in Iranian CML patients
| Authors/year | Response |
Mortality- %
(Cause) |
Progression to AP
or BP no. (%) |
Overall Survival
(%) |
Time to event end
points (%) |
|||
|---|---|---|---|---|---|---|---|---|
| HR (no, %) | MR (no, %) | CyR (no, %) | ||||||
| Adult | Jalaeikhoo H, et al./2011 (36) | 413 (99) | NA | NA | 7.4 (relapse, MI and car accident) |
46 (11 ) | 6-year OS (89) |
6-year EFS (83) |
| Mozaheb Z, et al./2014 (26) | 56 (94) | MR (28,46.8) | NA | 6.67 (progressive disease) |
8 (13.4) | 4-year OS (65) |
44-month EFS (65) | |
| Razmkhah F, et al./2010 (31) |
27 (90) | CMR (14,46.7) PMR (13,43.3) NMR (3,10) MMR (44.1, 52.97 and 60.75%) at 12, 18 and 24 months |
NA | NA | NA | NA | NA | |
| Payandeh M, et al./2015 (71) | NA | NA | NA | NA | NA | 5-year OS (90.5) |
NA | |
| Moshfeghi K, et al./2013 (19) | Iranian brand: 86% Indian brand: 86% |
Iranian brand: 46.5% Indian brand: 44.2% |
NA | NA | NA | NA | NA | |
| Golabchifar AA, et al./2014 (21) |
NA | MMR (31, 51.7) | CCyR (8,13.3) | NA | NA | NA | NA | |
| Salamizand H, et al./2015 (27) | 63 (90) | NA | CyR (49,70) | NA | NA | NA | NA | |
| Nekoohesh L, et al./2019 (35) | NA | MMR (15.38, 25.18, 44.1,52.97,60.75) at 3, 6, 12, 18, and 24 months | NA | NA | NA | NA a | NA a | |
| Payandeh M, et al./2018 (34) | NA | EMR (40%)MMR (28.33%) DMR (15%)CMR (16.67%) at 12 months |
NA | NA | NA | NA | NA | |
| Vatanmakanian M, et al./2019 (32) | CHR (88.8% in CP pts) at 6 months; (60% in AP pts) at 11 months; (50% in BP pts) | CMR (55.5% in CP pts)PMR (33.3% in CP pts) NMR (11.1% in CP pts) at 6 months; MMR (40% in AP pts) at 11 months;MMR (33.3% in BP pts) PMR (50% in BP pts) NMR (16.6% in BP pts) | NA | NA | NA | NA | NA | |
| Rostami G, et al./2017 (33) | NA | MMR (15 out of 25 pts with e13a2 transcript type; 30 out of 35 pts with e14a2 type) up to 24 months | CCRe (22 of the remaining 30 pts with e14a2 transcripts; five of the remaining 15 pts with e13a2 transcripts) up to 12 months | NA | NAb | NA | NA | |
| Safaei A, et al./2018 (28) | NA | MMR (72.5% of pts without ACA) | NA | NA | NA | NAc | NA | |
| Pediatric | Bahoush Gr, et al./2009 (20) | Early CP: 7 (100) Late CP: 6 (85.7) |
NA | CCyR (12,85.7) PCyR (1,7.1) |
14.3 (progressive disease) |
1 (7.15) | NA | 30-month PFS (85.7) |
| Hamidieh AA, et al./2013 (39) | 11 (57.9) | NA | CCyR (7,36.8) | 21 (hematologic relapse and progressive disease) |
8 (42.1) | 2-year OS (87) |
DFS (82) |
|
They are reported based on various BCR-ABLIS categories at different months.
One patient with e13a2 and another one with e14a2 transcript had disease progression within first 24 months of treatment.
Cum survival of 76 patients was calculated in this article: survival of patients with ACA; 49.7±11.1 months and survival of those without ACA; 77.3±3.1months. pt(s): patient(s). HR; hematologic response, CHR; complete hematologic response, NA; not available, CP; chronic phase, AP; accelerated phase, BP; blastic phase, MR; molecular response, EMR; early molecular response, MMR; major molecular response, DMR; deep molecular response, NMR; no molecular response, CMR; complete molecular response, ACA; additional cytogenetic aberrations, PMR; partial molecular response, CyR; cytogenetic response, CCyR; complete cytogenetic response, PCyR; partial cytogenetic response, CCRe; complete cytogenetic response equivalence, MI; myocardial infraction, OS; overall survival, EFS; event free survival, PFS; progression free survival, DFS; disease free survival